Additional file 3: of B-cell imaging with zirconium-89 labelled rituximab PET-CT at baseline is associated with therapeutic response 24Â weeks after initiation of rituximab treatment in rheumatoid arthritis patients
- Stefan Bruijnen (3552035)
- Michel Tsang-A-Sjoe (3552041)
- Hennie Raterman (3552050)
- Tamara Ramwadhdoebe (3552044)
- DaniĂŤlle Vugts (3552056)
- Guus van Dongen (3552047)
- Marc Huisman (180686)
- Otto Hoekstra (3552038)
- Paul-Peter Tak (356893)
- Alexandre Voskuyl (3497321)
- Conny van der Laken (3473156)
Publication date
November 2016
DOIAbstract
Appendix C. Quantitative tissue uptake of 89Zr-rituximab on whole body PET in responders vs. non-responders. An additional table with SUV of body organs like liver, spleen and vertebrae showing that there is no (significant) difference between responders and non-responders in organ uptake of 89Zr-rituximab. (DOCX 15Â kb
Add to ORKG